WallStreetZenWallStreetZen

NASDAQ: ADMA
Adma Biologics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ADMA stock forecasts and price targets.

Forecast return on equity

Is ADMA forecast to generate an efficient return?

Company
109.42%
Industry
67.13%
Market
179.62%
ADMA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ADMA forecast to generate an efficient return on assets?

Company
83.67%
Industry
31.85%
ADMA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ADMA earnings per share forecast

What is ADMA's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.92+48.89%
Avg 2 year Forecast
$1.20+93.58%
Avg 3 year Forecast
$1.60+157.47%
ADMA's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ADMA revenue forecast

What is ADMA's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$650.3M+27.46%
Avg 2 year Forecast
$794.0M+55.64%
Avg 3 year Forecast
$963.8M+88.91%
ADMA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ADMA earnings growth forecast

How is ADMA forecast to perform vs Biotechnology companies and vs the US market?

Company
36.37%
Industry
11.81%
Market
35.93%
ADMA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ADMA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ADMA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ADMA revenue growth forecast

How is ADMA forecast to perform vs Biotechnology companies and vs the US market?

Company
23.4%
Industry
35.72%
Market
13.42%
ADMA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ADMA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ADMA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADMA$15.02N/AN/A
GPCR$50.46$110.78+119.54%Strong Buy
DNTH$80.00$128.90+61.13%Strong Buy
ACAD$20.72$32.75+58.06%Buy
CORT$34.08$85.00+149.41%Buy
View Top Biotech Stocks

Adma Biologics Stock Forecast FAQ

What is ADMA's earnings growth forecast for 2026-2028?

(NASDAQ: ADMA) Adma Biologics's forecast annual earnings growth rate of 36.37% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.81%, and it is also forecast to beat the US market's average forecast earnings growth rate of 35.93%.

Adma Biologics's earnings in 2026 is $146,930,000.On average, 5 Wall Street analysts forecast ADMA's earnings for 2026 to be $219,844,735, with the lowest ADMA earnings forecast at $203,054,513, and the highest ADMA earnings forecast at $235,063,107. On average, 5 Wall Street analysts forecast ADMA's earnings for 2027 to be $285,838,643, with the lowest ADMA earnings forecast at $256,735,592, and the highest ADMA earnings forecast at $315,084,590.

In 2028, ADMA is forecast to generate $380,173,493 in earnings, with the lowest earnings forecast at $354,761,909 and the highest earnings forecast at $402,608,087.

If you're new to stock investing, here's how to buy Adma Biologics stock.

What is ADMA's revenue growth forecast for 2026-2028?

(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 23.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.42%.

Adma Biologics's revenue in 2026 is $510,173,000.On average, 5 Wall Street analysts forecast ADMA's revenue for 2026 to be $154,863,004,194, with the lowest ADMA revenue forecast at $148,206,455,225, and the highest ADMA revenue forecast at $160,042,966,272. On average, 5 Wall Street analysts forecast ADMA's revenue for 2027 to be $189,103,148,928, with the lowest ADMA revenue forecast at $180,998,592,168, and the highest ADMA revenue forecast at $195,402,459,133.

In 2028, ADMA is forecast to generate $229,525,905,870 in revenue, with the lowest revenue forecast at $220,256,750,740 and the highest revenue forecast at $236,563,509,521.

What is ADMA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ADMA) forecast ROA is 83.67%, which is higher than the forecast US Biotechnology industry average of 31.85%.

What is ADMA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ADMA) Adma Biologics's current Earnings Per Share (EPS) is $0.62. On average, analysts forecast that ADMA's EPS will be $0.92 for 2026, with the lowest EPS forecast at $0.85, and the highest EPS forecast at $0.99. On average, analysts forecast that ADMA's EPS will be $1.20 for 2027, with the lowest EPS forecast at $1.08, and the highest EPS forecast at $1.32. In 2028, ADMA's EPS is forecast to hit $1.60 (min: $1.49, max: $1.69).

What is ADMA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ADMA) forecast ROE is 109.42%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.